Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy

CompletedOBSERVATIONAL

Enrollment

104

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

March 27, 2023

Study Completion Date

March 27, 2023

Conditions

Dengue Virus Infection

Interventions

DRUG

CYD-TDV Dengue Vaccine

Pharmaceutical form:Solution Route of administration: Intramuscular

Trial Locations (1)

Universidade Federal do Paraná Site Number : 1, Curitiba

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY